MorphoSys, after Saying AbbVie ‘Failed,’ Defends Own Mixed Blood Cancer Data, Plots Approval Filings

The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.